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The objective of this thesis is to establish the functional role of the Frizzled-8 receptor 
and its cognate WNT ligands in lung diseases͕ with focus on its role in chronic obstructive 
pulmonary disease (CKWD). Lung diseases as CKWD͕ asthma and pulmonary fibrosis 
are characterised by aberrant inflammatory and repair processes that show overlap in 
expression of growth factors and inflammatory cytokines. The pathophysiology of these 
diseases is not yet fully understood and current treatment options are not curative. Zecent 
studies have indicated an important role for WNT signalling in the development of these 
lung diseases. We previously found the expression of the WNT receptor Frizzled-8 (FD8) 
to be increased in human lung fibroblasts of CKWD patients. This thesis will investigate the 
functional role of the FD8 receptor͕  and its cognate WNT ligands.
The WNT signalling pathway
The wingless/intergrase-1 (WNT) signalling pathway is essential to cell polarity and cell 
fate determination during embryonic development ΀1΁. /n adult tissue͕ WNT signalling 
contributes to tissue homeostasis via the maintenance of stem cell pluripotency͕  
inflammation͕ repair processes and self-renewal ΀2͕ 3΁. The WNT signalling pathway is 
made up of WNT ligands that can bind cell surface Frizzled (FD) receptors to activate 
downstream signalling cascades ΀4΁. Signalling that occurs via β-catenin is called canonical 
signalling͕ while all other routes are indicated as noncanonical signalling. 
WNT ligands
WNT ligands are cysteine-rich͕ glycosylated͕ lipid-modified secreted proteins that function 
as growth factors throughout the body. There are currently 1ϵ known mammalian WNT 
ligands  that have been defined by amino-acid structure instead of functional properties 
΀5͕ 6΁. All WNT ligands share a signal seƋuence for secretion͕ several highly charged amino 
acid residues and potential glycosylation sites ΀7΁͕ while the number of glycosylation sites 
diīers per WNT molecule. The cysteine residues in WNT ligands are important for the 
binding properties of the molecule. Kf the 23 cysteine residues found in WNT-1͕ 22 are 
conserved in the other WNT ligands ΀7͕ 8΁. This suggests a strong overlap in binding site 
interactions. WNT ligands can bind to the N-terminal cysteine-rich domain (CZD) of the 
FD receptors in a highly specific manner ΀ϵ΁. The crystal structure of yenopus WNT8 with 
mouse FD8 has been identified (figure 1) and shows four main regions of concentrated 
amino acid conservation͕ one of them being opposite of the WNT-binding patch for the 
FD receptor. This has been proposed to be a binding site for co-receptors ΀ϵ΁. 
 Secreted WNT ligands are strongly hydrophobic because of palmitoylation͕ 
which is why they preferably bind to the extracellular matrix (ECM) or associate with the 
cell membrane ΀10΁. Their hydrophobic nature also contributes to their short distance 
signalling range͕ however mechanisms have been described for long distance WNT 
signalling as well. /t has been suggested that both short and long distance transportation 
of WNT ligands is possible via transcytosis/retromer function in endosomal traĸcking 
vesicles ΀11͕ 12΁. Another suggested manner of extracellular transport of WNT ligands 
over short distances involves argosomesin the ECM. Argosomes are lipoprotein 
particles that can bind the palmitoylated WNT ligands ΀11΁. Additionally͕  heparan sulfate 








Figure 1: Xenopus WNT-8 (XWnt8) binding to the CRD of mouse FZD8 (Fz8-CRD) adapted from Janda et al. 
΀ϵ΁. The binding between WNT and FD resembles a hand palm where the ͚thumb͛ and ͚index finger͛ of yWnt8 
bind to two opposite sides of the Fz8-CZD. Kn the tip of the ͚thumb͕͛  a palmitic or palmitoleic acid (WAM) group 
is responsible for binding to the Fz8-CZD and the ͚index finger͛ is bound to the Fz8-CZD by hydrophobic amino 
acid contacts ΀ϵ΁. NTD: N-terminal domain.
WosƩranslational modifications͕ including palmitoylation and glycosylation appear to be 
necessary for WNT transport and function͕ although their precise roles are not yet fully 
elucidated. Walmitoylation by the acyl-transferase porcupine facilitates N-glycosylation 
΀14΁ and is necessary for WNT secretion ΀12͕ 15͕ 16΁ as well as binding to the FD receptor 
΀ϵ͕ 17͕ 18΁. The mechanism of WNT secretion into the extracellular space is not fully 
understood͕ but is facilitated by the protein complex Wntless/Evenness interrupted 
(Wls/Evi) ΀16͕ 1ϵ-21΁. Glycosylation by an oligosaccharyl transferase complex (KST) ΀14΁ 
increases WNT interactions with heparin sulphate proteoglycans on the cell surface of 
WNT responding cells ΀11΁. Specific interactions with GAG-modified proteins facilitate 
the extracellular movements of WNT ligands ΀10΁͕ but it has also been proposed that 
palmitoylation targets WNT ligands to specific extracellular domains ΀11΁͕ thereby 
influencing movement of WNT ligands. 
 At the time that WNT ligands were discovered͕ it was not clear how these growth 
factors activated downstream signalling. While the class of FD receptors was already 
known͕ it took several years before it was clear that they were the cognate receptors 
in the WNT signalling pathway ΀4΁. Now͕ a variety of WNT receptors is known. Apart 
from FD receptors͕ WNT ligands can bind the transmembrane tyrosine kinase-related 
receptor Zz< that has a WNT binding domain ΀22΁ and ZKZ2 that has a CZD motif similar 
to FD receptors ΀23΁. Zz< and ZKZ2 can function as co-receptors͕ but they are not 
indispensable for activation of WNT signalling as FD receptor dimerization upon binding 
can be suĸcient to activate the downstream signalling cascade ΀24΁. /n addition to Zz< 
and ZKZ2͕ also protein tyrosine kinase 7 (WT<7) and lipoprotein receptor-related protein 
(LZW)5/6 are known to function as co-receptors of the WNT signalling pathway. While 
co-receptors are not essential for WNT signalling͕ it is believed that they are important 







in both the canonical and noncanonical WNT signalling cascade ΀22΁͕ while activation of 
ZKZ2 ΀25΁ and WT<7 ΀26΁ (alone and together ΀27΁) have been shown to inhibit canonical 
signalling͕ and activate noncanonical signalling pathways. LZW5/6 is as co-receptor 
essential for canonical WNT signalling ΀28΁. 
Frizzled receptors
/n mammalian tissue͕ 10 FD subtypes are known. FD receptors are characterized 
by a large extracellular domain that is made up of an assumed signal seƋuence at the 
N-terminus followed by a seƋuence of 120 amino acid (primarily ɲ-helical proteins ΀ϵ΁) 
that contain 10 highly conserved cysteine residues called the CZD. The CZD appears to 
be the ligand binding site ΀8͕ ϵ΁ and is followed by a diīering region of 40 ʹ 100 amino 
acids that form a flexible͕ seven transmembrane segments and a cytoplasmic C-terminal 
tail ΀2ϵ͕ 30΁. The transmembrane segments are separated by short extracellular and 
cytoplasmic loops. FD receptors share several features with G protein coupled receptor 
(GWCZ)s ΀31͕ 32΁ and there are multiple indications that both canonical and noncanonical 
WNT signalling can involve G proteins ΀32΁. ,owever͕  the specific molecular mechanisms 
for FD activation are still unknown.
 WNT/FD signalling can be downregulated by zinc and ring finger (NZF)3 and 
ring finger protein (ZNF)43͕ which have E3 ubiƋuitin ligase activity that leads to turn-
over of activated FD receptors ΀33͕ 34΁. When a WNT ligand is bound͕ NZF3 expression 
is increased and as a negative feedback loop͕ a mechanism that acts to inhibit WNT 
signalling by internalizing the activated WNT/FD/LZW complex. /n this process of WNT 
receptor turn-over͕  the phosphoprotein Dishevelled (DsL) functions as an adapter protein 
by binding NZF3 and ZNF43 to FD ΀35΁. Next to WNT ligands͕ several FD receptors 
including FD8 can bind Z-spondins ΀36-3ϵ΁. Z-spondins enhance WNT signalling because 
of their binding properties to LGZ receptors͕ which act to neutralize the activity of NZF3 
and ZNF3 ΀40΁. /n contrast͕ specifically for the FD8 receptor͕  connective tissue growth 
factor ΀41΁ and insulin-like growth factor-binding protein-4 ΀42΁ can antagonize FD8 by 
direct binding.
 As stated before͕ lipid modification by palmitoylation of WNT ligands is necessary 
for FD binding ΀ϵ͕ 17͕ 18΁. Walmitoylated WNT ligands can interact with the CZD of FD 
receptors ΀ϵ΁. Because of the homology in FD structure͕ it is speculated that all FD 
CZDs will bind WNT ligands ΀43΁. /t is not clear how the WNT ligands or the FD receptors 
determine downstream signalling specificity. There are indications that FDs are the 
main players herein as substitution of amino acids in FD-CZD impacts on preferences of 
binding of WNT subtypes. For instance͕ Met14ϵ at the centre of the part where the WNT 
C-terminal CZD binds to the FD CZD is conserved in FD5 and FD10͕ but substituted 
by sal͕ Glu or Asp in FD1͕ FD2͕ FD3͕ FD6 and FD7 ΀ϵ΁. ,owever͕  because of the 
highly conserved binding sites in the FD CZD͕ it is unlikely that there is a large diīerence 
in aĸnity of individual WNT ligands for individual FD receptors ΀ϵ΁. /ndeed͕ any WNT 
ligand can activate several downstream signalling cascades͕ depending on the receptor 
that is expressed ΀25΁. More recently͕  it was proposed that most WNT ligands can bind 
to most FD receptors and that the downstream signalling that will be activated by a 
specific WNT/FD combination is dependent on the combination of WNT ligands and FD 
receptors present in a cell system ΀44΁. /n any case͕ binding of a WNT ligand to a FD 







by downstream signalling cascades. As mentioned earlier, DVL also facilitates the turn-
over of activated FZD receptors [35] and in this way functions both as an activator and an 
inhibitor of WNT signalling. 
Canonical WNT signalling
β-Catenin has a pivotal role in the canonical WNT signalling pathway. In the absence of 
an activated FZD receptor, β-catenin is phosphorylated and degraded by a destruction 
complex that is made up of Axin, glycogen synthase kinase (GSK)3, casein kinase (CK)1 
and adenomatosis polyposis coli (APC). If WNT and FZD form a ternary complex with 
co-receptor LRP5/6, intracellular DVL is activated and recruits Axin and GSK3 to the 
ternary complex. This leads to the disassembly of the β-catenin destruction complex and 
a subsequent accumulation of β-catenin. β-Catenin will then translocate to the nucleus, 
where it activates among others the T cell factor/lymphoid enhancer factor (TCF/LEF) 
transcription factors, resulting in the transcription of WNT responsive genes [48], such as 
Axin2 [49] and cyclin D1 [50].
Noncanonical WNT signalling
WNT ligands can also induce multiple β-catenin independent signalling pathways [32] 
which are called noncanonical signalling pathways. New noncanonical signalling pathways 
are still discovered, for instance activation of p38 mitogen activated protein kinase by WNT 
ligands has recently been shown [51-53]. Established noncanonical WNT signalling routes 
include WNT/RAC, WNT/RHO, WNT/RAP, WNT/ROR, WNT/planar cell polarity (PCP), WNT/
Ca2+ and WNT/cGMP signalling [54, 55]. Three noncanonical signalling pathways that are 
known to involve FZD activation, namely the WNT/PCP pathway that signals via RhoA/c-
Jun N-terminal kinase (JNK), the WNT/Ca2+ pathway that signals via calcium and the WNT/
cGMP pathway that signals via cyclic guanosine 3’5’-monophosphate (cGMP). 
WNT/PCP pathway
Activation of the WNT/PCP pathway can occur via a ternary WNT/FZD complex with co-
receptor RYK [56], ROR2 [57], PTK7 [26] or ROR2 and PTK7 combined [27]. WNT ligand 
binding results in the recruitment of intracellular DVL and the subsequent activation 
of small Rho GTPases to regulate actin cytoskeleton remodelling and the activation of 
JNK, which can have three effects. Rho/JNK signalling can regulate actin cytoskeleton 
remodelling, increase the intracellular calcium concentration and activate transcription 
factors thereby regulating gene expression [58].
WNT/Ca2+/cGMP pathway
Binding of a WNT ligand to its FZD receptor supposedly activates a heterotrimeric G 
protein [32, 59], thereby regulating intracellular calcium [31] and cGMP levels [60]. In 
the WNT/Ca2+ pathway, the activated G protein induces the activation of phospholipase 
C (PLC), which stimulates the conversion of phosphatidylinositol 4,5-biphosphate (PIP2) 
to diacylglycerol (DAG) and inositol triphosphate (IP3) via hydrolysis. IP3 can initiate a rise 
in intracellular calcium via its receptors on the endoplasmic reticulum. DAG will activate 
protein kinase C (PKC). Activation of PKC leads to actin cytoskeleton remodelling. Calcium 
can also activate calmodulin to induce contraction in smooth muscle cells and calmodulin 







(NFAT) transcription factors͕ which then translocate to the nucleus and activate gene 
transcription ΀61΁. /n addition͕ next to intracellular calcium levels͕ FD2 has been shown 
to regulate intracellular cGMW levels via G protein activation ΀62͕ 63΁. Whosphodiesterase 
(WDE)6 is the proposed eīector for this signalling route ΀63͕ 64΁.
WNT signalling in chronic lung diseases
WNT-1 (at that time int1) was discovered as a proto oncogene in a mouse model for breast 
cancer ΀65΁. Since then͕ aberrant WNT signalling has been implicated in multiple types 
of cancer͕  including lung cancer ΀66΁. WNT signalling is also found to play an important 
role in (embryonic) lung development ΀67-6ϵ΁ as well as inflammatory processes ΀70΁ and 
tissue repair and remodelling in the adult lung ΀71-74΁. These pathophysiologic processes 
have their implications for chronic lung diseases such as CKWD͕ asthma and pulmonary 
fibrosis.
CKWD
CKWD is a complex͕ progressive lung disease with a high prevalence especially in the 
elderly that is the fourth cause of death worldwide with a predicted increased burden in 
the future. /n the Western world͕ the main risk factor of CKWD is cigareƩe smoking. Kther 
important risk factors include outdoor air pollution͕ indoor air pollution for instance 
caused by biomass cooking͕ heating in inadeƋuately ventilated rooms or occupational 
dust and chemicals ΀75΁. The vast majority (80-ϵ0й) of CKWD patients are (ex-)smokers͕ 
although only 10-15й of the smoking population develops CKWD. Kver the last decades͕ 
it has become apparent that genetic susceptibility is also underlying CKWD development 
΀76΁. /n addition͕ impairment in lung growth and lung development (by any cause) is also 
associated with a higher risk for CKWD development later in life ΀77͕ 78΁.
 CKWD is defined by four grades (1-4) of severity in the global initiative for chronic 
obstructive lung disease (GKLD) guidelines. These grades reflect the degree of airflow 
obstruction that is expressed as the forced expiratory volume in 1 second (FEsЕ) aŌer 
full inspiration͕ divided by the total volume of exhaled air upon forced expiration (FsC). 
CKWD is diagnosed by a ratio of FEsЕ/FsC ф 0.7. A lower ratio reflects more severe airflow 
obstruction. The development of airflow obstruction in CKWD is progressive and not 
fully reversible. This obstruction is caused by a combination and interplay of increased 
airway resistance and decreased elastic recoil. /ncreased airway resistance is caused by 
bronchoconstriction͕ chronic inflammation͕ mucus hypersecretion and remodelling of the 
small airways i.e. increased airway smooth muscle mass͕ myofibroblast diīerentiation and 
abundant ECM production. Decreased elastic recoil is caused by parenchymal destruction 
leading to a loss of alveolar wall aƩachments called emphysema͕ contributing to changes 
in airway resistance ΀75΁.
 CKWD is characterised by a predominant neutrophilic inflammation ΀7ϵ΁. /nhaled 
noxious particles or gases first encounter epithelial cells and macrophages͕ causing 
oxidative stress͕ damage and activation of pro-inflammatory pathways ΀80΁. Activated 
epithelial cells and macrophages produce pro-inflammatory cytokines͕ such as interleukin 
(/L)-1β͕ /L-6͕ tumor necrosis factor (TNF)-ɲ and the chemokine ligands CyCL1͕ CyCL8͕ 
CyCLϵ͕ CyCL10 and CyCL11 ΀81͕ 82΁. /L-1β͕ TNF-ɲ and /L-6 amplify inflammatory processes 
and are increased in CKWD ΀81΁. CyCL1 and CyCL8 are also increased in CKWD and aƩract 







differentiate to macrophages in the lung [79], to help in the first line of defence against 
foreign invaders. CXCL9, CXCL10 and CXCL11 attract T helper (T�)1 lymphocytes and type 
1 cytotoxic T cells (Tc1) via CXCR3. However, T lymphocytes in COPD are predominantly 
CD8+ cytotoxic cells. Also T�2-type cytokines, such as IL-4, are elevated in COPD [82], 
especially during exacerbations [83]. Epithelial damage can also lead to the production of 
growth factors such as transforming growth factor (TGF)-β and epidermal growth factor 
(EGF) [82] and both growth factors are increased in COPD [82]. EGF regulates mucus 
secretion from goblet cells in the epithelium via its receptor EGFR [84, 85] and TGF-β is a 
key factor in fibroblast activation. 
 The fibroblast plays a key role in repair and remodelling processes in COPD. 
TGF-β activates fibroblasts to produce ECM proteins and promotes their differentiation 
into myofibroblast [86-88]. Myofibroblasts have a more contractile profile than 
fibroblasts, which is characterized by an increased expression of contractile markers such 
as α-smooth muscle(sm)-actin [87, 89]. In turn, the composition of the ECM regulates 
the structural and functional properties of the lung and the cells embedded herein [89-
91]. ECM protein can be broken down by proteases such as matrix metallopeptidase/
protease (MMP)-9. An imbalance in the breakdown and production of ECM proteins can 
lead to the development of emphysema [92]. In contrast, fibroblasts in the small airways 
are activated by growth factors to produce ECM proteins and contribute to the repair 
process. A shift in the balance to this side contributes to the development of fibrotic 
processes leading to airway wall thickening [93].
 COPD is an umbrella-term for small airways disease, chronic bronchitis and 
parenchymal destruction. Within the COPD patient population, there are different 
phenotypes. For instance, not all COPD patients have additional chronic bronchitis. 
Chronic bronchitis is defined by chronic cough and idiopathic sputum production for at 
least three months per year for two consecutive years [75]. Enhanced EGFR signalling 
upon epithelial damage can cause mucus cell metaplasia [94]. Mucus cell metaplasia is 
characterized by more mucus in the airways both by an increased production of mucus 
and by a decreased mucociliary transport from the airways [95], and manifests itself as 
chronic mucus hypersecretion (CMH). CMH is a risk factor for COPD [96] and is associated 
with bronchial inflammation and accelerated lung function decline [97].
 COPD is considered as a treatable disease [75], however current treatment 
options are not curative. The most effective treatment option is smoking cessation, as this 









Figure 2: The natural history of chronic airflow obstruction, adapted from Fletcher and Peto [98]. FEV1 declines 
gradually and continuously with increasing age. Smoking causes a steeper decline in lung function in susceptible 
smokers, but not in non-susceptible smokers. Smoking cessation at any age almost fully restores the natural 
pattern of lung function decline albeit at a lower starting point [98].
Anti-inflammatory treatment in COPD consists of inhaled corticosteroids and/or oral 
PDE4 inhibitors [75]. Inhaled corticosteroids dampen the inflammation in some of the 
COPD patients, in particular when there is an additional eosinophilic inflammation, but 
there is no hard evidence that they can improve lung function decline. This minimal 
effect is mainly due to corticosteroid resistance [99]. PDE4 inhibitors are added to 
corticosteroid or bronchodilator treatment in severe COPD with chronic bronchitis and 
a high risk of exacerbations [75]. Bronchodilators (adrenergic β-receptor agonists) can 
improve lung function [100, 101], and there are indications that they also affect the 
underlying inflammation [102, 103] and remodelling [103], but there is no evidence yet 
that they can stop or reverse the long-term decline in lung function, indicating that new 
pharmacological approaches are urgently awaited.
Asthma
Asthma is a heterogeneous obstructive airway disease that affects people of all ages 
and has an increasing incidence worldwide. The mechanisms responsible for asthma 
are multifactorial, involving both genetic and environmental factors. Allergy is amongst 
the strongest predispositions, but it cannot explain the prevalence of asthma alone 
and non-atopic factors exist as well [104, 105]. In addition to exposure to indoor and 
outdoor allergens (allergic asthma), for instance also exercise or cold air, irritants and 
viral infections (non-allergic asthma) can trigger an asthmatic reaction, leading to airflow 
obstruction. Airflow obstruction in asthma is at least in part reversible and assessed 
with a bronchodilator reversibility test. Asthma is further characterised by bronchial 
hyperresponsiveness that is often associated with airway inflammation and remodelling 







severity is deĮned according to the composite asthma severity index (CASI) that is based 
on combined information on impairment, risk and the amount of medication needed to 
maintain control [108].
 Dast cells play an important role in inflammation in asthma and can be activated 
directly by allergenic factors via immunoglobulin E or indirectly through non-allergenic 
factors and epithelial derived cytokines. hpon activation, mast cells release their 
contractile mediators, such as histamine and leukotrienes that lead to bronchoconstriction 
and attract inflammatory cells. In contrast to COPD, airway inflammation in asthma 
is mainly eosinophilic in nature and characteriǌed by a T«2-type immune response, 
involving cytokines such as I>-4, I>-5, I>-9 and I>-13 [81, 109-112]. I>-4 and I>-13 stimulate 
B-cells to synthesiǌe immunoglobulin E (IgE), I>-5 promotes eosinophilic inflammation, 
I>-9 stimulates mast cell proliferation and I>-13 is a main regulator of mucus production 
in the airways. Similar to COPD, I>-1β, TEF-ɲ and I>-ϲ also play a pro-inflammatory role in 
asthma [113, 114]. 
 Airway remodelling in asthma is induced by T'F-β, E'F and vascular endothelial 
growth factor (VE'F) and includes structural changes such as airway smooth muscle 
hypertrophy and hyperplasia, goblet cell metaplasia, bronchial vascular remodelling 
as well as basement membrane thickening and subepithelial Įbrosis [115-118]. 
Structural changes in the airways contribute to the persistent component of airway 
hyperresponsiveness [119], lung function decline and persistent airflow obstruction 
[120]. Parenchymal destruction is a process that by deĮnition does not occur in asthma, 
but can be seen in asthma patients with additional COPD [121, 122].
 Airflow obstruction is in most asthmatic patients spontaneously reversible 
or reversible by treatment with bronchodilators or corticosteroids. Eevertheless, 
some patients remain symptomatic despite treatment and treatment does not cure 
the underlying inflammation and remodelling [123, 124]. For instance, neutrophilic 
inflammation in severe asthma patients does not respond to the standard corticosteroid 
treatment [125].
Pulmonary Įbrosis
Pulmonary Įbrosis is characterised by the abundant formation of scar tissue in the 
parenchymal lung tissue and is presumed to be caused by repetitive micro inũuries to the 
lung as a result of cigarette smoke, environmental exposure to larger dust particles such 
as metal dust, silica or coal dust, viral infections or a connective tissue disorder [12ϲ]. 
Pulmonary Įbrosis is determined by recognition of a distinct pattern of interstitial Įbrosis/
scar tissue through high resolution computed tomography (,ZCT) and is not deĮned by 
different stages of disease. hltimately, chronic oxygen deĮciency in the blood due to 
impaired diffusion capacity leads to organ failure and eventually death [12ϲ]. Pulmonary 
Įbrosis is often a secondary effect of other diseases, but in the case of idiopathic 
pulmonary Įbrosis (IPF), the exact cause is unknown. IPF is a chronic progressive Įbrotic 
interstitial pneumonia that upon diagnosis has an estimated median survival rate of two 
to Įve years [127].
 thile it was previously thought that the Įbrosis is a conseƋuence of chronic 
inflammation, recent studies indicate that repeated epithelial damage in genetically 
predisposed subũects may be of more importance [12ϲ, 127]. Zepeated inũury to alveolar 







foci that consist of myofibroblasts and scar tissue. Fibroblasts at the damaged site 
diīerentiate under influence of TGF-β into myofibroblasts. /n addition͕ fibroblast growth 
factor (FGF)͕ platelet derived growth factor (WDGF) and sEGF contribute to the (vascular) 
remodelling seen in pulmonary fibrosis ΀126΁. While remodelling in asthma and CKWD 
occurs mainly in the (small) airways͕ in pulmonary fibrosis͕ the parenchymal lung tissue is 
mostly aīected ΀128͕ 12ϵ΁.
 Zecently͕  new anti-fibrotic therapies are being used in /WF patients͕ or have 
entered Whase /-/// studies͕ according to the ATS/EZS/JZS/ALAT statement on /WF ΀126΁. 
Still͕ according to this oĸcial document͕ the current medicinal treatment options for /WF 
are without definitive͕ confirmed advantages ΀126΁. /n general͕ there is a need for new 
and beƩer treatment options for the above mentioned lung diseases and for this͕ we 
need to get a beƩer understanding of the underlying mechanisms that contribute to the 
development of these diseases.
WNT signalling in CKWD͕ asthma and pulmonary fibrosis
While CKWD͕ asthma and pulmonary fibrosis are distinctly diīerent diseases͕ there are 
some important aspects that overlap͕ most evidently the changes in fibroblast function. 
Next to their structural role͕ fibroblasts exert cellular responses associated with airway 
remodelling and inflammation͕ including proliferation͕ ECM protein production and the 
secretion of inflammatory cytokines. Kne of the main players in airway remodelling is 
TGF-β ΀86΁. TGF-β can be secreted from the epithelium upon damage and subseƋuently 
activate fibroblasts͕ which leads to dysregulated ECM production and diīerentiation 
of fibroblasts into the more contractile myofibroblast ΀87΁. Damaged epithelium can 
also secrete /L-1ɲ͕ /L-1β͕ TNF-ɲ and EGF ΀81΁ which can stimulate fibroblasts to secrete 
inflammatory cytokines ΀130΁. /n this way͕  fibroblasts also play a role in airway inflammation 
by regulating inflammatory cytokine secretion.
 There are multiple indications that the WNT signalling pathway is involved in 
airway remodelling and inflammation in various lung diseases. WNT/β-catenin signalling 
was increased in ovalbumin-challenged mice and allergen-induced airway inflammation 
and remodelling in these animals were aƩenuated by treatment with β-catenin small 
interfering (si)ZNA ΀131΁. /n a mouse model of allergic airway disease͕ pharmacological 
inhibition of GS<-3β reduced the expression of MhC5AC ΀132΁. As GS<-3 normally inhibits 
canonical WNT signalling͕ these data suggest that canonical WNT signalling negatively 
regulates allergen-induced mucus secretion in the airways. ,owever͕  it should be realized 
that GS<-3 has additional functions in the cell ΀133΁. Nuclear β-catenin was found to 
be upregulated in /WF patients ΀134΁͕ but whether this is a cause or a conseƋuence of 
the disease is not clear ΀135΁. /n addition͕ several studies found activation of WNT/β-
catenin signalling in /WF ΀71͕ 136΁͕ or showed that inhibition of WNT/β-catenin signalling 
aƩenuates (experimental) /WF ΀137-13ϵ΁. /n CKWD͕ decreased canonical WNT signalling 
was found in emphysematous lesions ΀140͕ 141΁.
 Furthermore͕ TGF-β has recently been shown to interact with the WNT signalling 
pathway ΀74͕ 142-144΁. Zecent studies from our group showed that β-catenin is reƋuired 
for TGF-βЕ-induced extracellular matrix production by airway smooth muscle cells ΀73΁ 
and that TGF-β-induced WNT-5B and FD8 mZNA expression is increased in pulmonary 
fibroblasts of CKWD patients ΀74΁. /t was also reported that high FD8 gene expression 







Furthermore, nicotine induced epithelial-mesenchymal transition via T'F-β1 and tET-
3A/β-catenin signalling in human bronchial epithelial cells [14ϲ]. In addition, inhibiting 
DV> suppressed T'F-β-induced signalling in murine Įbroblasts and reduced bleomycin-
induced pulmonary Įbrosis in a mouse model [147]. 
 T'F-β is able to induce tET-1-inducible signalling pathway protein (tISP)-1 in 
human bronchial smooth muscle cells and both T'F-β and tISP-1 induced bovine smooth 
muscle proliferation and hypertrophy [148]. Ovalbumin challenge induced tISP-1 and a 
tISP-1 antibody partly suppressed ovalbumin-induced airway smooth muscle hypertrophy 
in a rat animal model [148]. Additionally, a single nucleotide polymorphism (SEP) in the 
tISP-1 gene is associated with lower FEV1 in COPD [149], further strengthening a possible 
important role for tISP-1 in obstructive lung diseases. tISP-1 as well as tET-7B transcript 
levels were speciĮcally upregulated in mice with bleomycin-induced acute lung inũury and 
mice with bleomycin-induced pulmonary Įbrosis [150]. 
 Eext to tISP-1, stimulation with T'F-β increased tET-5A in normal human lung 
Įbroblasts and in human airway smooth muscle cells [151]. tET-5A mZEA and protein 
expression was also found to be increased in Įbroblasts from lung tissue of patients with 
interstitial pneumonia compared with normal lung Įbroblasts [152]. In addition, our group 
previously showed tET-5A to be increased in asthmatic airway smooth muscle cells 
[144] and in whole lung tissue of COPD patients [53]. In line with this, we showed that 
T'F-β induced tET-5A in human airway smooth muscle cells [144] and that this occurs 
via T'F-β-activated kinase (TA<)-1 [153]. tET-5A in turn regulated T'F-β-induced ECD 
production in human airway smooth muscle cells [144] and human lung Įbroblasts [152], 
and increased Įbroblast proliferation [152]. Furthermore, tET-5A increased resistance to 
,2O2-induced apoptosis and tET-5A knockdown by speciĮc siZEA induced the apoptosis 
marker caspase-3 [152], indicating that tET-5A is a proliferative ligand that regulates 
remodelling. Additionally, tET-5A [154, 155] and FD5 [154] have recently been shown 
to function as pro-inflammatory in the lung, whereas tET/β-catenin signalling inhibits 
neutrophil attraction by alveolar epithelial cells [15ϲ]. 
 There are several other tET ligands that have been shown to play a role in 
the pathophysiology of lung diseases. tET-1 and tET-2 have been shown to regulate 
proliferation of lung Įbroblasts induced by conditioned medium of mesenchymal stem cells 
[157]. tET-4 expression was shown to be increased in epithelial cells of COPD patients, 
but downregulated after stimulation with cigarette smoke extract [52, 158]. tET-7A mZEA 
expression is increased in sputum of asthma patients compared to sputum of healthy 
controls [131]. tET-10B has also been shown to act anti-inflammatory by modifying the T 
cell response to allergen-challenge in wild-type (tT) and tET-10B-deĮcient mice [159]. 
 Eext to tET ligands, tET antagonists play a role in lung diseases. Tobacco smoke 
causes an upregulation of secreted Friǌǌled-related protein (SFZP)-2, an inhibitor of tET 
signalling, in epithelial cells [1ϲ0], suggesting inhibition of tET signalling by smoking may 
lead to the development of emphysema. Interestingly, SFZP-1 was found to be upregulated 
in the lungs of emphysema patients, while its expression is also necessary for normal 
alveolar development [1ϲ1], indicating dual roles for tET signalling in developmental and 
disease mechanisms. In another study, SFZP-1 was shown to counteract T'F-β-induced 
signalling in pulmonary Įbroblasts and alveolar epithelial cells, however it had no effect on 
bleomycin-induced Įbrosis in a mouse model [1ϲ2], indicating that the effects of SFZP-1 







Scope of this thesis
As described above͕ WNT ligands and FD receptors appear to play a role in inflammatory 
and remodelling processes that contribute to the development of various lung diseases. 
Changes in fibroblast function contribute to chronic lung diseases such as CKWD͕ asthma 
and pulmonary fibrosis. We previously found WNT-5A͕ WNT-5B and FD8 expression 
to be increased in lung fibroblasts of patients with CKWD. Therefore͕ we hypothesized 
that WNT-5A/WNT-5B and FD8 signalling functionally contribute to the development of 
inflammation and remodelling in the lungs and the overall aim of this thesis is to establish 
the functional roles of WNT-5A/WNT-5B and FD8 in various lung diseases͕ with focus on 
its role in CKWD.
 In chapter 2͕ we investigated the role of FD8 signalling in vitro in TGF-β-induced 
fibroblasts activation and explored the ligands of FD8 in these eīects. Furthermore͕ we 
studied a possible role for FD8 in bleomycin-induced TGF-β signalling in vivo͕ using FD8 
deficient mice. 
 TGF-β induces ECM proteins like fibronectin and collagen /ɲ1͕ however it 
reduces decorin expression and even more so in CKWD patients ΀163΁. TGF-β and decorin 
are known to operate in a negative feedback loop were TGF-β reduces decorin ΀163΁͕ but 
decorin is able to bind TGF-β thereby reducing TGF-β-induced signalling ΀164΁. Decorin 
has recently been shown to be able to bind W/SW-1 ΀165΁. Based on their structures͕ 
we hypothesized that decorin is also able to bind WNT-5B. Therefore we investigated in 
chapter 3 whether decorin was able to reduce functional WNT-5B signalling͕ by studying 
the eīect of recombinant decorin on WNT-5B-induced fibroblast activation. 
 In chapter 4͕ we studied whether there is a specific role for FD8 in the 
chronic bronchitis phenotype. Acute cigareƩe smoke-induced airway inflammation was 
studied in vivo in wild-type and FD8 deficient mice. We performed genetic association 
studies and lung expression Ƌuantitative trait loci (eYTL) analyses for FD8 to evaluate 
polymorphisms in FD8 and their relationship to tissue expression in chronic bronchitis. 
Next͕ we investigated whether FD8 was diīerentially expressed in fibroblasts of GKLD 
grade 4 CKWD patients with CM, and fibroblasts of patients without CM,. To investigate 
the functional eīects of this potential diīerence͕ we studied inflammatory cytokine 
secretion from these fibroblasts and their eīect on mucus secretion in vitro using air-
liƋuid-interface (AL/) cultured primary airway epithelial cells. 
 Airways are in direct contact with the outside world and epithelial cells function 
as the first defence barrier. hpon epithelial damage͕ signalling from the epithelium to the 
underlying fibroblasts is altered. /n CKWD͕ asthma and pulmonary fibrosis͕ TGF-β is an 
important player in epithelial-fibroblast communication and this is an important aspect in 
disease development. TGF-β has recently been shown to interact with the WNT signalling 
pathway ΀74͕ 142-144΁͕ but if WNT signalling is involved͕ and if so in what way is not known. 
WNT ligands and FD receptors are diīerentially expressed in epithelial and mesenchymal 
cells and since WNT ligands are known to function in an autocrine/paracrine manner over 
short distances͕ it is likely that they play a role in the communication between epithelial 
and mesenchymal cells. There are some indications that WNT signalling is indeed involved 
in epithelial-mesenchymal communication or at least on mesenchymal function. For 
instance͕ epithelial WNT-7B was found to be necessary for smooth muscle development 
through regulation of mesenchymal diīerentiation ΀166΁. To elaborate further on the 







cells and Įbroblasts, we investigated in chapter 5 which tET ligands are involved herein. 
To study this, we used co-cultures of either primary airway Įbroblasts of COPD grade 4 
patients or DZC-5 human lung Įbroblasts with A>I differentiated primary airway epithelial 
cells of healthy donors. 
 Others have shown that tET-5A is upregulated in asthma patients and functions 
as a ligand for FD8 [144]. In chapter 6, we investigated whether FD8 has a functional role 
in allergen-induced inflammation and remodelling in vivo. tild-type and FD8 deĮcient 
mice were sensitiǌed to ovalbumin and subseƋuently challenged with ovalbumin or saline 
(control group).
 In chapter 7, all the results presented in this thesis are discussed within the 
broader perspective of the development of inflammatory and remodelling mechanisms 
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